Intellipharmaceutics Financial Statements From 2010 to 2025
| IPCIFDelisted Stock | USD 0.04 0.00 0.00% |
Check Intellipharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intellipharmaceutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Intellipharmaceutics financial statements analysis is a perfect complement when working with Intellipharmaceutics Valuation or Volatility modules.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Current Valuation Analysis
Intellipharmaceutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Intellipharmaceutics Current Valuation | 4.47 M |
Most of Intellipharmaceutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellipharmaceutics International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Intellipharmaceutics International has a Current Valuation of 4.47 M. This is 99.97% lower than that of the Pharmaceuticals sector and 99.9% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Intellipharmaceutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Intellipharmaceutics's current stock value. Our valuation model uses many indicators to compare Intellipharmaceutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intellipharmaceutics competition to find correlations between indicators driving Intellipharmaceutics's intrinsic value. More Info.Intellipharmaceutics International is rated fifth overall in return on asset category among its peers. It also is rated fifth overall in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intellipharmaceutics' earnings, one of the primary drivers of an investment's value.About Intellipharmaceutics Financial Statements
Intellipharmaceutics stakeholders use historical fundamental indicators, such as Intellipharmaceutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Intellipharmaceutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Intellipharmaceutics' assets and liabilities are reflected in the revenues and expenses on Intellipharmaceutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Intellipharmaceutics International. Please read more on our technical analysis and fundamental analysis pages.
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. The company was founded in 1998 and is based in Toronto, Canada. Intellipharmaceutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |